However, a Phase II clinical trial in patients with moderate to severe RA using the first-in-class small-molecule RIPK1 inhibitor GSK2982772 (NCT02858492) failed to see significant clinical improvement beyond potential reductions in bone erosions [136]. This evidence concerns the gene RIPK1 and rheumatoid arthritis.